Featured Research

from universities, journals, and other organizations

Cancer drugs: Better, cheaper

Date:
June 4, 2012
Source:
University of California - San Francisco
Summary:
Cancer drug development is known to be too slow, costly and fraught with failure. Now the US Food and Drug Administration is issuing recommendations for breast cancer trials that would substantially accelerate patient access to new medications while lowering the time and cost of drug development.

Cancer drug development is known to be too slow, costly and fraught with failure. Now the U.S. Food and Drug Administration is issuing recommendations for breast cancer trials that would substantially accelerate patient access to new medications while lowering the time and cost of drug development.

Related Articles


The new regulatory guidelines are based in part on groundbreaking, national breast cancer research led by UCSF.

The FDA "draft guidance,'' issued last week, is aimed at helping medical researchers gain swifter approval for promising drugs in the early stages of development for breast cancer. The guidance represents the federal agency's "current thinking on this topic,'' according to the draft.

The guidelines are discussed in the current issue of The New England Journal of Medicine.

The FDA's new approach is based on a trial design being tested in a clinical study known as I-SPY 2, launched by UCSF in conjunction with a private-public partnership that includes the FDA, the National Institutes of Health, pharmaceutical companies and academic medical centers.

I-SPY 2 combines personalized medicine with a novel investigational design to identify women at high risk of early breast cancer recurrence. It is underway at 19 major cancer research centers around the country.

"Better options for patients with high-risk breast cancer are urgently needed,'' said Janet Woodcock, MD, director of the Center for Drug Evaluation and Research at the FDA. "The FDA guidance explains how a promising drug identified in trials such as I-SPY 2 could be evaluated for FDA approval, so patients could have rapid access if the drug proved better than current treatments.''

Traditionally, patients with early-stage breast cancer must wait years to receive new cancer drugs, which are generally tested first in patients with later stage metastatic disease and approved for use in more curable, early stage cancer only after additional clinical trials.

It can take more than a decade to bring a new cancer drug to the market and cost more than $1 billion.

The need for new regulatory approaches was discussed in a December 2011 commentary in the Journal of the American Medical Association (JAMA) co-authored by Woodcock and Laura Esserman, MD, MBA, director of the Carol Franc Buck Breast Care Center at the UCSF Helen Diller Family Comprehensive Cancer Center.

"The major losers in this inefficient approach are the patients who would benefit from new treatments,'' wrote Esserman and Woodcock in their JAMA article.

But combining novel trial designs with new approaches for accelerated approval would hasten the pace through the research pipeline to bring medications to patients at far lower costs, the authors wrote.

The new FDA recommendations would speed up approval of drugs tested prior to surgical removal of tumors in certain types of high-risk patients with localized, early stage disease. The guidance centers on neoadjuvant therapy for breast cancer -- the administration of therapeutic agents prior to surgery. The FDA said it may now grant approval to medications that have shown clinical benefit, based on data from patients receiving this type of neoadjuvant treatment whose invasive cancers have disappeared by the time of surgery, termed "pathologic complete response.''

In I-SPY 2, a patient's cancerous tumors are left in place for approximately six months, rather than being immediately removed surgically. Several new agents are tested in combination with standard chemotherapy in an effort to improve the chance of the tumor shrinking and completely disappearing -- before surgery -- in women with high risk breast cancer. The trial is designed to learn which patients will have the most benefit from new targeted therapies, which will help to speed access under the FDA's new guidelines.

I-SPY 2 can test new treatments in half the traditional time, and with significantly fewer participants which will dramatically lower costs.

"We are truly excited to see that the FDA is supportive of trials like I-SPY 2,'' said Esserman, the co-principal investigator of I-SPY 2. "This really moves us much closer to getting the right drugs to the right patients at a time when they can be cured.''

The FDA is accepting comment on the new recommendations through July.

"This guidance represents the work of literally hundreds of individuals who are dedicated to harnessing the best of science and medicine to achieve real progress against cancer,'' said Anna D. Barker, PhD, professor and director of Transformative Healthcare Networks and co-director of the Complex Adaptive Systems Initiative at Arizona State University. She is the former deputy director of the National Cancer Institute.

I-SPY 2 is being conducted under the auspices of the Biomarkers Consortium, a public-private partnership led by the Foundation for the National Institutes of Health that includes representatives from the NIH, FDA, and multiple pharmaceutical companies and academic research centers.

Scientists from the National Cancer Institute, FDA, pharmaceutical and biotechnology companies, as well as breast cancer patient advocates also contributed to the design of I-SPY 2, which is managed by FNIH and Quantum Leap Healthcare Collaborative with support from Quintiles, a global biopharmaceuticals service provider. Funding for I-SPY 2 is provided by non-profit foundations including The Safeway Foundation, several pharmaceutical companies, and other private sector and philanthropic donors.


Story Source:

The above story is based on materials provided by University of California - San Francisco. Note: Materials may be edited for content and length.


Cite This Page:

University of California - San Francisco. "Cancer drugs: Better, cheaper." ScienceDaily. ScienceDaily, 4 June 2012. <www.sciencedaily.com/releases/2012/06/120604155743.htm>.
University of California - San Francisco. (2012, June 4). Cancer drugs: Better, cheaper. ScienceDaily. Retrieved October 30, 2014 from www.sciencedaily.com/releases/2012/06/120604155743.htm
University of California - San Francisco. "Cancer drugs: Better, cheaper." ScienceDaily. www.sciencedaily.com/releases/2012/06/120604155743.htm (accessed October 30, 2014).

Share This



More Health & Medicine News

Thursday, October 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Mind-Controlled Prosthetic Arm Restores Amputee Dexterity

Mind-Controlled Prosthetic Arm Restores Amputee Dexterity

Reuters - Innovations Video Online (Oct. 29, 2014) A Swedish amputee who became the first person to ever receive a brain controlled prosthetic arm is able to manipulate and handle delicate objects with an unprecedented level of dexterity. The device is connected directly to his bone, nerves and muscles, giving him the ability to control it with his thoughts. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Google To Use Nanoparticles, Wearables To Detect Disease

Google To Use Nanoparticles, Wearables To Detect Disease

Newsy (Oct. 29, 2014) Google X wants to improve modern medicine with nanoparticles and a wearable device. It's all an attempt to tackle disease detection and prevention. Video provided by Newsy
Powered by NewsLook.com
Can Drinking Milk Lead To Early Death?

Can Drinking Milk Lead To Early Death?

Newsy (Oct. 29, 2014) Researchers in Sweden released a study showing heavy milk drinkers face an increased mortality risk from a variety of causes. Video provided by Newsy
Powered by NewsLook.com
Obama: The US Will Not 'run and Hide' From Ebola

Obama: The US Will Not 'run and Hide' From Ebola

AP (Oct. 29, 2014) Surrounded by health care workers in the White House East Room, President Barack Obama said the U.S. will likely see additional Ebola cases in the weeks ahead. But he said the nation can't seal itself off in the fight against the disease. (Oct. 29) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins